Cilostazol - CAS 73963-72-1
Catalog number: 73963-72-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H27N5O2
Molecular Weight:
369.46
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
Cilostazol is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.
Purity:
>98%
Synonyms:
AT2266; CI919; Pd107779; NSC629661; AT 2266; CI 919; Pd 107779; NSC 629661; AT-2266; CI-919; Pd-107779; NSC-629661
MSDS:
Inquire
InChIKey:
RRGUKTPIGVIEKM-UHFFFAOYSA-N
InChI:
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
Canonical SMILES:
C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
1.The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey.
DE Donato G1, Setacci F, Galzerano G, Mele A, Ruzz U, Setacci C. J Cardiovasc Surg (Torino). 2016 Apr 1. [Epub ahead of print]
BACKGROUND: Although international guidelines recommend cilostazol as first-line therapy for peripheral arterial disease (PAD ) because it improves the symptoms and quality of life, it remains an underused agent for amputation-free survival. The objective of this study is to evaluate the practice among Italian physicians of the use of cilostazol in patients suffering from peripheral arterial disease (PAD).
2.The Effect of High Dose Cilostazol and Rosuvastatin on Periprocedural Myocardial Injury in Patients with Elective Percutaneous Coronary Intervention.
H A1, N E1, S A1, S C1, K D1, C A1, E T1, A T1, O C Y1, M G2, T B1, M M1. Zhonghua Minguo Xin Zang Xue Hui Za Zhi. 2015 Jul;31(4):292-300.
BACKGROUND: The aim of our study was to assess the effect of pretreatment with cilostazol and rosuvastatin combination before elective percutaneous coronary intervention (PCI) on peri-procedural myocardial injury (PPMIJ).
3.Effect of Cilostazol on Cerebral Vasospasm and Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage: A Randomized, Double-Blind, Placebo-Controlled Trial.
Matsuda N1, Naraoka M, Ohkuma H, Shimamura N, Ito K, Asano K, Hasegawa S, Takemura A. Cerebrovasc Dis. 2016;42(1-2):97-105. doi: 10.1159/000445509. Epub 2016 Apr 13.
BACKGROUND: Several clinical studies have indicated the efficacy of cilostazol, a selective inhibitor of phosphodiesterase 3, in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage (SAH). They were not double-blinded trial resulting in disunited results on assessment of end points among the studies. The randomized, double-blind, placebo-controlled study was performed to assess the effectiveness of cilostazol on cerebral vasospasm.
4.Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis.
Chen Y1, Pandiri I1, Joe Y1, Kim HJ1, Kim SK1, Park J1, Ryu J2, Cho GJ2, Park JW1, Ryter SW3, Chung HT1. Oxid Med Cell Longev. 2016;2016:3949813. doi: 10.1155/2016/3949813. Epub 2016 Jan 6.
The selective type-3 phosphodiesterase inhibitor cilostazol and the antihyperlipidemic agent probucol have antioxidative, anti-inflammatory, and antiatherogenic properties. Moreover, cilostazol and probucol can regulate mitochondrial biogenesis. However, the combinatorial effect of cilostazol and probucol on mitochondrial biogenesis remains unknown. Endoplasmic reticulum (ER) stress is a well-known causative factor of nonalcoholic fatty liver disease (NAFLD) which can impair mitochondrial function in hepatocytes. Here, we investigated the synergistic effects of cilostazol and probucol on mitochondrial biogenesis and ER stress-induced hepatic steatosis. A synergistic effect of cilostazol and probucol on HO-1 and mitochondrial biogenesis gene expression was found in human hepatocellular carcinoma cells (HepG2) and murine primary hepatocytes. Furthermore, in an animal model of ER stress involving tunicamycin, combinatorial treatment with cilostazol and probucol significantly increased the expression of HO-1 and mitochondrial biogenesis-related genes and proteins, whereas it downregulated serum ALT, eIF2 phosphorylation, and CHOP expression, as well as the lipogenesis-related genes SREBP-1c and FAS.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 192819-27-5 CDC801

CDC801
(CAS: 192819-27-5)

A potent, orally active and dual inhibitor of phosphodiesterase 4 (PDE4) (IC50= 1.1 μM) and tumor necrosis factor-α (TNF-α) (IC50= 2.5 μM).

CAS 111786-07-3 RGW2938

RGW2938
(CAS: 111786-07-3)

A phosphodiesterase inhibitor

CAS 106730-54-5 Olprinone

Olprinone
(CAS: 106730-54-5)

Olprinone(Loprinone) is a selective phosphodiesterase 3 (PDE3) inhibitor.

CAS 68475-42-3 Anagrelide

Anagrelide
(CAS: 68475-42-3)

Anagrelide is a phosphodiesterase inhibitor with antiplatelet activity with IC50 value of 36 nM for inhibition of phosphodiesterase 3. It inhibits the maturatio...

CAS 1440898-61-2 Deltarasin

Deltarasin
(CAS: 1440898-61-2)

Deltarasin inhibits the interaction of RAS with PDEδ with KD of 41 nM. Inhibition of PDEδ-KRAS interaction by Deltarasin suppresses proliferation of human pancr...

CAS 83-67-0 Theobromine

Theobromine
(CAS: 83-67-0)

Theobromine is the primary alkaloid found in cocoa and chocolate. As a phosphodiesterase inhibitor, theobromine prevents the phosphodiesterase enzymes from conv...

CAS 939055-18-2 FIPI

FIPI
(CAS: 939055-18-2)

FIPI, a derivative of halopemide, is a potent and selective phospholipase D (PLD) inhibitor with IC50 values of 20 and 25 nM for PLD2 and PLD1 respectively. It ...

CAS 139755-83-2 Sildenafil

Sildenafil
(CAS: 139755-83-2)

An orally active selective type 5 cGMP phosphodiesterase inhibitor.

Chemical Structure

CAS 73963-72-1 Cilostazol

Quick Inquiry

Verification code

Featured Items